Day One Biopharmaceuticals, Inc. (DAWN) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
395 Oyster Point Boulevard
Brisbane, CA 94080
United States of America (the)
Phone
650 484 0899
Website
Sector
Healthcare
Industry
Biotechnology
Employees
181
First IPO Date
May 27, 2021
| Name | Title | Pay | Year Born |
| Jeremy Bender | Chief Executive Officer, President & Director | 1.2M | 1971 |
| Adam Dubow | General Counsel | 762,995 | 1967 |
| Charles N. York | Chief Operating Officer & Chief Financial Officer | 873,625 | 1977 |
| Lauren Merendino | Chief Commercial Officer | 0 | 1976 |
| Heather Adkins Huet | Chief Scientific Officer | 0 | N/A |
| Joey Perrone | Senior Vice President of Finance & Investor Relations | 0 | N/A |
| John Stubenrauch | Chief Technology Officer | 0 | N/A |
| Jaa Roberson | Chief People Officer | 0 | N/A |
| Davy Chiodin | Chief Development Officer | 0 | N/A |
| Elly Barry | Chief Medical Officer | 0 | N/A |
| Michael J. Vasconcelles | Head of Research & Development | 0 | 1963 |
Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients experiencing recurrent or worsening low-grade glioma. Additionally, the company is advancing Pimasertib, an oral small molecule designed to inhibit mitogen-activated protein kinase kinases 1 and 2. Established in 2018, Day One Biopharmaceuticals, Inc. maintains its primary operations in South San Francisco, California.